Hanmi Pharmaceutical Co. Ltd. 13D and 13G filings for :
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-20 8:54 pm Sale | 2025-03-18 | 13D | Aptose Biosciences Inc. APTO | Hanmi Pharmaceutical Co. Ltd. | 508,710 19.900% | -2,480,705 (-82.98%) | Filing |
| 2024-04-26 12:54 pm Unchanged | 2024-04-24 | 13D | Aptose Biosciences Inc. APTO | Hanmi Pharmaceutical Co. Ltd. | 99,647 19.020% | 0 (Unchanged) | Filing |
| 2024-02-02 6:05 pm Purchase | 2024-01-31 | 13D | Aptose Biosciences Inc. APTO | Hanmi Pharmaceutical Co. Ltd. | 99,647 22.170% | 70,175 (+238.11%) | Filing |
| 2023-09-11 6:23 pm Purchase | 2023-09-06 | 13D | Aptose Biosciences Inc. APTO | Hanmi Pharmaceutical Co. Ltd. | 29,472 12.070% | 29,472 (New Position) | Filing |